<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283474</url>
  </required_header>
  <id_info>
    <org_study_id>PR-XG005-03-PK-01</org_study_id>
    <nct_id>NCT04283474</nct_id>
  </id_info>
  <brief_title>Phase 1 XG005-03 Topical Study</brief_title>
  <official_title>A Phase 1, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XG005-03 (Topical) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xgene Pharmaceutical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xgene Pharmaceutical Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, randomized, single-blinded, placebo-control, ascending single and multiple dose of
      the PK, safety, and tolerability of XG005-03 topical formulation in Healthy Volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-blind, placebo-controlled study which will investigate the PK, safety and
      tolerability of XG005-03 topical formulation, in three ascending concentrations after single
      and multiple topical applications in healthy subjects. The trial consists of two parts: a
      single ascending dose (SAD; Part 1) and a multiple ascending dose (MAD; Part 2). The MAD
      study will begin after the SAD portion of the study is complete.

      The study will consist of 4 weeks of screening period, treatment period (1 day of dosing for
      SAD and 6.5 days for MAD), and 14 days of safety follow-up period. Each subject will serve as
      his/her own control, as the XG005-03 and placebo will be applied on contralateral legs.
      Application of XG005-03 or placebo to a particular leg will be randomly assigned.

      Approximately 36 healthy subjects will be enrolled. Eighteen healthy subjects (3 alternates
      per dose group) in Part 1 (SAD) and Part 2 (MAD), who fulfill eligibility criteria will
      receive the study drug: XG005-03 (1%, 5%, and 10%) and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">November 24, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Analyses</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>peak concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Analyses</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>time to peak concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Analyses</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>terminal elimination rate constant (Kel)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic of XG005-03 in 1%, 5%, and 10% concentrations</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>half-life (t½)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Analyses</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>area under the concentration-time curve from time 0 to the last measurable concentration timepoint (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Analyses</measure>
    <time_frame>Day 1 to 4 days after last dose</time_frame>
    <description>area under the concentration-time curve, extrapolated to infinity (AUC0-∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Adverse Event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>ECG-heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>ECG-PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>ECG-QRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>ECG-QT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>ECG-QTc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Skin Assessment Grading-Burger and Bowman scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Vital Sign-Systolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Vital Sign-Diastolic Blood Pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Vital Sign-Pulse Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Vital Sign-Tympanic Temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Analyses</measure>
    <time_frame>treatment to follow up period, a average 20 days</time_frame>
    <description>Vital Sign-Respiratory Rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>XG005-03</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XG005-03 in 3 dose levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in all cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XG005-03</intervention_name>
    <description>3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation</description>
    <arm_group_label>XG005-03</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo topical formulation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy males or females between 18 and 55 years of age

          2. BMI 18.0 to 30.0 kg/m2

          3. Non-pregnant, non-breastfeeding female subjects

        Exclusion Criteria:

          1. Unstable or severe illness

          2. Skin infection or lesion

          3. Subjects with scars, moles, tattoos at application site

          4. Expose to excessive UV

          5. Hypersensitivity or allergy to NSAID
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Xu, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Xgene Pharmaceutical Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katherine Mudge</last_name>
    <phone>+61 431 739 345</phone>
    <email>Katherine.Mudge@cmax.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rhys Hamson</last_name>
    <phone>+61 423 605 724</phone>
    <email>Rhys.Hamson@cmax.com.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMAX Clinical Research Pty Ltd</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Mudge</last_name>
      <phone>+61 431 739 345</phone>
      <email>Katherine.Mudge@cmax.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Rhys Hamson</last_name>
      <phone>+61 423 605 724</phone>
      <email>Rhys.Hamson@cmax.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Guy Ludbrook, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

